The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer

[1]  J. Saucerman,et al.  Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. , 2021, Journal of molecular and cellular cardiology.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Xueqin Chen,et al.  PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1) , 2020, Autophagy.

[4]  Yi Ding,et al.  Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer , 2020, Cell Death & Disease.

[5]  Jingkui Tian,et al.  Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib , 2020, Cell Death & Disease.

[6]  Yun Yang,et al.  Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways , 2020, Oxidative medicine and cellular longevity.

[7]  Bo Hu,et al.  Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma , 2020, Cell Death & Disease.

[8]  G. Ji,et al.  Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial , 2020, BMJ Open.

[9]  J. Muntané,et al.  Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer , 2020, Redox biology.

[10]  Zhijian Jin,et al.  Cathepsin L promotes angiogenesis by regulating the CDP/Cux/VEGF-D pathway in human gastric cancer , 2020, Gastric Cancer.

[11]  Masayuki Yamamoto,et al.  The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway , 2020, Molecular and Cellular Biology.

[12]  H. Keun,et al.  Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells , 2020, British Journal of Cancer.

[13]  Zhenggang Zhu,et al.  The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis , 2019, Oncogene.

[14]  L. Tang,et al.  China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy , 2019, Cancer communications.

[15]  H. Li,et al.  Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma , 2019, Clinical and Translational Oncology.

[16]  Z. Duan,et al.  Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma , 2019, International journal of cancer.

[17]  Ting Chen,et al.  Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells , 2019, Journal of experimental & clinical cancer research : CR.

[18]  E. Giannoni,et al.  Lactate: A Metabolic Driver in the Tumour Landscape. , 2019, Trends in biochemical sciences.

[19]  Xin-Zu Chen.  Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China. , 2019, JAMA oncology.

[20]  Hans Clevers,et al.  A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. , 2018, Cell stem cell.

[21]  A. Cervantes,et al.  NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer , 2018, Clinical Cancer Research.

[22]  Tingting Wu,et al.  Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. , 2018, Biochemical and biophysical research communications.

[23]  E. Giannoni,et al.  Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. , 2018, Cell metabolism.

[24]  Masayuki Yamamoto,et al.  The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. , 2018, Physiological reviews.

[25]  Yahiya Y. Syed.  Anlotinib: First Global Approval , 2018, Drugs.

[26]  F. Du,et al.  Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.

[27]  M. Zheng,et al.  Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor , 2018, Cancer science.

[28]  M. Jauberteau,et al.  Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis , 2017, Oncogene.

[29]  S. Broutin,et al.  Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. , 2017, International journal of pharmaceutics.

[30]  Bingya Liu,et al.  Cancer‐associated fibroblast‐derived Lumican promotes gastric cancer progression via the integrin β1‐FAK signaling pathway , 2017, International journal of cancer.

[31]  Dakeun Lee,et al.  Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas , 2017, Gastric Cancer.

[32]  Tara Srinivasan,et al.  Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing , 2017, Nature Medicine.

[33]  Zhenggang Zhu,et al.  IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway , 2017, Oncotarget.

[34]  D. Hanahan,et al.  Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling , 2016, Cell reports.

[35]  M. Dowsett,et al.  miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. , 2016, Cancer research.

[36]  Ying Huang,et al.  The complexity of the Nrf2 pathway: beyond the antioxidant response. , 2015, The Journal of nutritional biochemistry.

[37]  S. Kulp,et al.  Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. , 2014, Carcinogenesis.

[38]  A. Gnatt,et al.  Oncogene PKC&egr; controls INrf2–Nrf2 interaction in normal and cancer cells through phosphorylation of INrf2 , 2013, Journal of Cell Science.

[39]  Y. Qu,et al.  Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. , 2013, Cancer letters.

[40]  Y. Toiyama,et al.  Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer , 2012, British Journal of Cancer.

[41]  Bauke Ylstra,et al.  Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer , 2012, Gut.

[42]  J. Lee,et al.  A Novel Role for BDNF-TrkB in the Regulation of Chemotherapy Resistance in Head and Neck Squamous Cell Carcinoma , 2012, PloS one.

[43]  L. Coussens,et al.  Immune microenvironments in solid tumors: new targets for therapy. , 2011, Genes & development.

[44]  Pierre Sonveaux,et al.  Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.

[45]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[46]  Ming Zhou,et al.  Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol , 2010, Molecular Cancer.

[47]  Y. Mohri,et al.  Neurotrophic receptor, tropomyosin-related kinase B, as a chemoresistant marker in oesophageal cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[48]  B. Jessen,et al.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[49]  C. Thiele,et al.  Inactivation of glycogen synthase kinase-3β contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells , 2007, Molecular Cancer Therapeutics.

[50]  A. Mesecar,et al.  Identification of the highly reactive cysteine 151 in the chemopreventive agent-sensor Keap1 protein is method-dependent. , 2007, Chemical research in toxicology.

[51]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[52]  Paul Talalay,et al.  Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers , 2004, Proceedings of the National Academy of Sciences of the United States of America.